Kasvu Therapeutics has raised €30 million in Series A funding led by Hadean Ventures to advance KTX-0141 towards clinical development for major depressive disorder.

The financing will support IND/CTA-enabling work and Phase 1/1b development of KTX-0141, a small-molecule TrkB positive allosteric modulator designed to enhance neuroplasticity without activating 5-HT2A. Kasvu expects clinical development to begin in the second half of 2027, with an initial efficacy assessment including a control arm.